The pharma company could earn its first drug approval in January 2020. What happens after that?
News & Analysis: Epizyme
The company put a clinical hold from 2018 behind it and submitted its first-ever new drug application.
It was a great day for the overall market. Find out why these stocks stood out.
A new update on its epigenetics drug, tazemetostat, has kindled investor optimism.
These stocks helped lead the market higher. Find out why.
The biotech reported new data for tazemetostat in lymphoma at a key industry conference.
On a rocky day for the market, these stocks climbed. Find out why.
Despite a falling market, these stocks gained ground. Find out why.
The biotech has won additional fast-track designations for its lead drug, tazemetostat.
Selling shares at a discount will do that.